Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial
Authors:
- Prabhat Kumar SharmaPSPrabhat Kumar Sharma
- Sagar Vivek RedkarSRSagar Vivek Redkar
- Abhishek Madhav KarmalkarAKAbhishek Madhav Karmalkar
- Sumit AnandSASumit Anand
- Vijaykumar Shivajirao PatilVPVijaykumar Shivajirao Patil
- Ansari Rizwanahmed NurulhasanANAnsari Rizwanahmed Nurulhasan
- Patel Manan BharatkumarPBPatel Manan Bharatkumar
- Vijaykumar BargeVBVijaykumar Barge
- Shalin J. ShahSSShalin J. Shah
- Chintan B. PatelCPChintan B. Patel
- Animesh ChoudharyACAnimesh Choudhary
- Kanugula SudheerKSKanugula Sudheer
Open Access
- 23 March 2026
- journal article
- Published by Elsevier in Metabolism Open
- Vol. 30, 100460
Abstract
No abstract availableKeywords
Funding Information
- Zydus Lifesciences
This publication has 23 references indexed in Scilit:
- Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe American Journal of Cardiology, 2024
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialThe Lancet, 2021
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trialThe Lancet, 2018
- Bariatric Surgery and Long-term Durability of Weight LossJAMA Surgery, 2016
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2010
- Obesity-related non-communicable diseases: South Asians vs White CaucasiansInternational Journal of Obesity, 2010
- The Y-Y paradoxThe Lancet, 2004